| Names | |
|---|---|
| IUPAC name 2-(4-Hydroxyphenyl)ethyl β-D-glucopyranoside | |
| Systematic IUPAC name (2R,3S,4S,5R,6R)-2-(Hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]oxane-3,4,5-triol | |
| Other names Salidroside Rhodioloside Tyrosol glucoside | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.224.258 |
PubChem CID | |
| UNII | |
CompTox Dashboard (EPA) | |
| |
| |
| Properties | |
| C14H20O7 | |
| Molar mass | 300.307 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Salidroside (rhodioloside) is a glucoside of tyrosol found in the plant Rhodiola rosea . [1] It has been studied, along with rosavin, as one of the potential compounds responsible for the putative antidepressant and anxiolytic actions of this plant. [2] [3] Salidroside may be more active than rosavin, [4] even though many commercially marketed Rhodiola rosea extracts are standardized for rosavin content rather than salidroside.
Salidroside was shown to improve glucose homeostasis and alleviate diabetic retinopathy in obese mice. [5] [6] The antioxidant, anti-inflammatory and neuroprotective effects of salidroside have also been reported. [7] [8] [9]
The salidroside biosynthetic pathway in Rhodiola rosea was described in 2018. [10] Rhodiola contains a pyridoxal phosphate-dependent 4-hydroxyphenylacetaldehyde (4-HPAA) synthase that converts tyrosine to 4-HPAA, which is further reduced to tyrosol by 4-HPAA reductase. Rhodiola contains a regio-selective tyrosol:UDP-glucose 8-O-glucosyltransferase that glycosylates tyrosol to produce salidroside.